<DOC>
	<DOCNO>NCT01008163</DOCNO>
	<brief_summary>The purpose trial determine dosage select evaluate efficacy safety YY-351 .</brief_summary>
	<brief_title>A Dose-Finding , Efficacy Safety Study YY-351 Patients With Type 2 Diabetes</brief_title>
	<detailed_description>Ginseng widely study treatment diabetes , dyslipidemia obesity . Interestingly , addition ginseng root , ginseng berry leaf also show reduce blood glucose diabetic model . In recent study , ginsam , vinegar extraction Panax ginseng , enrich ginsenoside Rg3 , distinct beneficial effect glucose metabolism body weight control obese animal model insulin resistance change expression gene involve glucose fatty acid metabolism . Our group also publish Rg3 improves insulin signal glucose uptake primarily stimulate expression IRS-1 GLUT4 . Thus , evaluate efficacy , dose-response relationship safety ginsam , vinegar extract Panax ginseng .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<criteria>Previous diagnosis Type 2 diabetes ( 3months ) Patients age 18 year FPG level range : 126 270mg/dL HbA1c : 7.0 12.0 % Pregnant woman , Breast feeding , actively try come pregnant Patients Type 1 DM , gestational diabetes secondary diabetes FPG level range : ≥ 270mg/dL HbA1c : ＜ 7.0 , ＞12.0 % Patient take medicine may affect blood sugar control ( i.e.systemic glucocorticoid ) Patients diabetic complication history case would affect efficacy safety evaluation ( i.e . Thyroid disorder , Cushing 's Syndrome , Multiple ovarian cystoma , pheochromocytoma ) Patients Chronic hepatitis , hepatitis B , C ( except healthy HBV carrier ) Liver disease ( AST or/and ALT &gt; 2 × ULN ( upper limit normal ) ) Patients Kidney disorder ( Cr &gt; 2.0 )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2009</verification_date>
	<keyword>diabetes</keyword>
</DOC>